| Sector |
Trading
|
Compare with Sector peers |
| Industry |
Trading
|
Compare with Industry peers |
| Website | http://www.achyuthealthcare.com | |
| Market Cap | 13.48 Cr. | |
| Enterprise Value(EV) | 13.46 Cr. | 2021-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.01 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 119.83 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 16.47 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 1.21 | Calculated using Price: 20.00 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 0.67 Cr. | 6,741,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Achyut Healthcare is engaged in the trading of Pharmaceutical Products. The company has business operations in both domestic and international markets in the countries namely UAE, Kenya, and Nigeria. The company is located in Ahmedabad, Gujarat. Since incorporation, it was the company‘s vision and mission has been to remained focused towards the pharmaceutical business of trading and supplying of superior quality products to its customers based on their customizations and requirements, which has enabled it to expand its business operations globally and dive into manufacturing business on its own plants rather than outsourcing and procuring from third parties. Business area of the company The company is engaged in trading of Cenzure, Arpimune, Azathioprine IP, Everomimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP, Infrared thermometer, Ascorbic Acid Coated Vitamin C, Calcium carbonate oyster, Cellulose acetate Phthalate, Chlorthalidone IP, Cross Carmalose Sod IP/USP, DI Basic Calcium Phosphate IP, DI Ethyl Phthlate, Diltiazem Hydrochloride IP, Easy Coat Fc Titanium Dioxide, Escitalopram IP, Escitalopram Oxalate, Favipiravir among many other products. Major Events and Milestones
|
||
Company Profile
Achyut Healthcare is engaged in the trading of Pharmaceutical Products. The company has business operations in both domestic and international markets in the countries namely UAE, Kenya, and Nigeria. The company is located in Ahmedabad, Gujarat. Since incorporation, it was the company‘s vision and mission has been to remained focused towards the pharmaceutical business of trading and supplying of superior quality products to its customers based on their customizations and requirements, which has enabled it to expand its business operations globally and dive into manufacturing business on its own plants rather than outsourcing and procuring from third parties.
Business area of the company
The company is engaged in trading of Cenzure, Arpimune, Azathioprine IP, Everomimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP, Infrared thermometer, Ascorbic Acid Coated Vitamin C, Calcium carbonate oyster, Cellulose acetate Phthalate, Chlorthalidone IP, Cross Carmalose Sod IP/USP, DI Basic Calcium Phosphate IP, DI Ethyl Phthlate, Diltiazem Hydrochloride IP, Easy Coat Fc Titanium Dioxide, Escitalopram IP, Escitalopram Oxalate, Favipiravir among many other products.
Major Events and Milestones
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
|
| 3 Month |
|
|
| 6 Month |
|
|
| 1 Year |
|
|
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 3 years | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | -7.46 | 6.91 | 3.47 | |
| Return on Capital Employed (%) | 7.21 | 9.48 | 4.92 | |
| Return on Assets (%) | -6.33 | 5.58 | 2.00 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Shh. Funds | 0 | 0 | 0 | |
| Non Curr. Liab. | 0 | |||
| Curr. Liab. | 0 | 0 | 0 | |
| Minority Int. | ||||
| Equity & Liab. | 0 | 0 | 0 | |
| Non Curr. Assets | 0 | 0 | ||
| Curr. Assets | 0 | 0 | 0 | |
| Misc. Exp. not W/O | ||||
| Total Assets | 0 | 0 | 0 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 1 | 0 | 0 | |
| Other Income | 0 | |||
| Total Income | 1 | 0 | 0 | |
| Total Expenditure | -1 | 0 | 0 | |
| PBIDT | 0 | 0 | 0 | |
| Interest | ||||
| Depreciation | ||||
| Taxation | 0 | |||
| Exceptional Items | ||||
| PAT | 0 | 0 | 0 | |
| Adjusted EPS |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 0 | |
| Cash Fr. Inv. | ||||
| Cash Fr. Finan. | ||||
| Net Change | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 0 | 0 | 0 |
|
Thu, 19 May 2022
Board Meeting Intimation for Board Meeting Intimation For Intimation Of Board Meeting To Be Held On Thursday May 26 2022 Achyut Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 inter alia to consider and approve Achyut Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 inter alia to consider and approve Intimation of Board Meeting to be held on Thursday May 26 2022 |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sun, 15 May 2022
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Parag Sandipkumar Dave Designation: Company Secretary EmailId: mahendrazenith@hotmail.com Name of the Chief Financial Officer: Jigen Modi Designation: MD and CFO EmailId: mahendrazenith@hotmail.com Date: 15/05/2022 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sun, 15 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.
Date: 15/05/2022 |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
No Scans Found |
Equities
M.F.
Sectors